CytoMed Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
CytoMed Therapeutics has a total shareholder equity of SGD11.2M and total debt of SGD441.7K, which brings its debt-to-equity ratio to 3.9%. Its total assets and total liabilities are SGD12.4M and SGD1.1M respectively.
Key information
3.9%
Debt to equity ratio
S$441.70k
Debt
Interest coverage ratio | n/a |
Cash | S$9.00m |
Equity | S$11.24m |
Total liabilities | S$1.12m |
Total assets | S$12.37m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: GDTC's short term assets (SGD10.1M) exceed its short term liabilities (SGD716.9K).
Long Term Liabilities: GDTC's short term assets (SGD10.1M) exceed its long term liabilities (SGD407.8K).
Debt to Equity History and Analysis
Debt Level: GDTC has more cash than its total debt.
Reducing Debt: Insufficient data to determine if GDTC's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GDTC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: GDTC has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 24.9% each year.